• VARSITY Trial Data

    Professor Stefan Schreiber presents the VARSITY clinical trial results comparing vedolizumab to adalimumab in the treatment of ulcerative colitis.
    To get an insight in to study design and treatment efficacy, watch the video here.   

  • ECCO 2019

    The two Takeda sponsored satellite symposia from ECCO 2019 entitled ‘Treatment decisions with advanced therapies: Comparative evidence in ulcerative colitis’ and ‘Evolving models of care in Crohn’s disease: Identifying and treating patients at risk of disease progression’ can be watched here.

  • GUT-SELECTIVE VS ADVANCED SYSTEMIC THERAPIES

    Professor Jean Frédéric Colombel notes that while gut-selective and advanced systemic therapies have been compared in meta-analyses and using real-world data, only head-to-head clinical trials can elucidate comparative efficacy and safety. Watch the highlight video from ECCO 2019 here.

  • Anti-integrins in IBD

    What role do integrins play in IBD? Why would targeting this pathway be an attractive treatment option?

  • Anti-integrin clinical trials

    Anti-integrin-based therapeutics have been demonstrated to be efficacious in both ulcerative colitis and Crohn’s disease. Find out the relevant clinical trial data for ulcerative colitis and Crohn’s disease.

 

Welcome to the anti-integrins in IBD Knowledge Centre

Latest updates:

ECCO 2019 - The 14th Congress of ECCO highlighted current trends in patient management and best practices for treating patients with IBD. Watch expert faculty provide valuable insight on key issues during the Takeda sponsored satellite symposia on both Crohn’s disease and ulcerative colitis.

UEG Week 2018 - Watch key presentations from the Takeda sponsored satellite symposia that focused on achieving rapid and sustained efficacy in IBD therapies across both Crohn’s disease and ulcerative colitis.

The growing understanding of the immunopathogenesis of inflammatory bowel disease (IBD) has provided a variety of novel therapeutic targets. Apart from the tumour necrosis factor-α mediated pathway, which is the target of the first marketed biologics in this indication, several other pathways are involved in triggering an inflammatory response.

Marketed therapies for the management of moderately to severely active IBD inhibit cytokine signalling pathways or target leukocyte trafficking.

Figure 1: Marketed therapies for the management of moderately to severely active IBD inhibit cytokine signalling pathways or target leukocyte trafficking. Anti-p40; anti-p40 antibodies; Anti-TNFs, anti-tumour necrosis factors; IBD, inflammatory bowel disease; ICAM-1, intracellular cell adhesion molecule; IL-12R, interleukin-12 receptor; IL-23R, interleukin-23 receptor; JAK, Janus kinase; MAdCAM-1, mucosal cell adhesion molecule; TNFα, tumour necrosis factorα; TNFR, tumour necrosis factor receptor; VCAM-1, vascular cell adhesion molecule (adapted from Cimzia® Summary of Product Characteristics, 2014; Entyvio® Summary of Product Characteristics, 2014; Humira® Summary of Product Characteristics, 2008; Remicade® Summary of Product Characteristics, 2009; Stelara® Summary of Product Characteristics, 2013; Simponi® Summary of Product Characteristics, 2014; Tysabri® Prescribing Information, 2016; Xeljanz® Summary of Product Characteristics, 2017).

In both ulcerative colitis and Crohn’s disease, the invasion of the intestinal mucosa by leukocytes is now an important clinical focus (Park & Jeen, 2018). Anti-integrin therapies which block the action of integrins and endothelial cell adhesion molecules include natalizumab and also vedolizumab which targets trafficking of leukocytes. Find out more about their mechanisms of action, explore the relevant study data and review recent data shared at Congresses.

Anti-integrins

What role do integrins play in IBD? Why would targeting this pathway be an attractive treatment option?

Anti-integrin clinical trials

Anti-integrin-based therapeutics have been demonstrated to be efficacious in both ulcerative colitis and Crohn’s disease. Find out the relevant clinical trial data for ulcerative colitis and Crohn’s disease.

Congresses and Symposia

Want to know more about what’s going on in IBD? This key events and meetings section can help you keep up-to-date.

References
Login/ Register Maximise Minimise

Alternatively login via